Role of IL-1β on RBC velocities in capillaries.

<p>Vertical dashed lines represent initial application of topical agent (prior to agent is topical saline). Points represent the average velocity of RBCs within the three areas viewed at the indicated times (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0040126#s4" target="_blank">Methods</a> and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0040126#pone-0040126-g002" target="_blank">Fig 2</a> for details). Similar to <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0040126#pone-0040126-g004" target="_blank">Fig. 4A,B</a>, two regression lines were calculated. The first regression line uses the first four viewing intervals. The second line uses the fourth through seventh viewing intervals. Error bars represent standard error of the mean. <b>A</b>) B6.CAST.11M mice given a topical application of IL-1β had a more negative slope of RBC velocities in capillaries for phase 1 (asterisk), but not phase 2, compared to C57BL/6J mice given IL-1β. Each animal group had n = 5; slope of regression line phase 1, p = 0.002. <b>B</b>) B6.CAST.11M mice given a topical application of rat anti-mouse IL-1β plus LT had a tendency for a less negative slope in phase 2 compared to B6.CAST.11M receiving rat IgG1 isotype control antibody plus LT, but did not reach significance (p = 0.075). Each animal groups, n = 5. <b>C</b>) B6.CAST.11M mice given a topical application of IL-1β had a smaller area under regression line compared to C57BL/6J mice given IL-1β (p = 0.009) (corresponding to panel A) (# indicates arbitrary units). <b>D</b>) B6.CAST.11M mice given a topical application of rat anti-mouse IL-1β plus LT had a larger area under the regression line compared to B6.CAST.11M receiving rat IgG1 isotype control antibody plus LT (p = 0.047) (corresponding to panel B).